Dylan L Bellavance, MD
Family Practice · Corte Madera
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 14
- 3 carriers
- Offices
- 4
- Since medical school
- 8 years
- University of Texas at Austin Dell Medical School, 2018
Offices
4 locations · Carbon Health Medical Group of California PC · Marin Community Clinic · One Medical Group Inc
Looking this up.
Hospitals listed: Marinhealth Medical Center · Novato Community Hospital. That is not proof they admit you there this week.
Plans that list them
14 plans · 3 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Bellavance’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
14 of 14 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Astiva Health C-SNP WOW - NorCal (HMO C-SNP) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Premier Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Savings Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Marinhealth Medical CenterGreenbrae, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of MarinHealthPatients rate it 3 of 5 · 76% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.66 (3.59 to 7.73) · 1,505 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.177, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025
- Novato Community HospitalNovato, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 84% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0, Oct 2024 – Sep 2025
See every measure and the patient survey for Marinhealth Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 0 worse of 7 measures. Readmissions: 3 better, 8 the same, 0 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.66 (3.59 to 7.73) · 1,505 cases | Worse | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.177 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.85 (0 to 1.83) · 1,056 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.04 (0.72 to 1.36) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 167.34 (112.58 to 222.09) · 57 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.9 · 47 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.5 · 119 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.6 · 257 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.5 · 428 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 11.4 · 477 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.3 · 197 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.1 · 2,827 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.18 (0 to 0.38) · 6,990 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.41) · 6,838 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.41 (0 to 3) · 664 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.86 (1.4 to 4.33) · 1,436 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.38 (3.68 to 17.08) · 705 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.38 (0.72 to 8.04) · 672 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.66 (0.18 to 3.15) · 300 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.56 (0 to 1.25) · 5,550 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.4 · 76 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.396 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.1 · 275 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22 · 427 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -20.3 · 289 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 3.3 · 494 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -4.9 · 499 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.9 · 435 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.5 (3.6 to 8.4) · 93 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 11.2 (7.8 to 16) · 93 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.6 · 84 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.5 · 53 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 111 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13 (10.3 to 16.5) · 2,119 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.1 (0.8 to 1.4) · 670 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,233 patients answered, 19% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 68% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 74% |
| Staff "always" explained | 56% |
| Yes, staff "did" give patients this information | 85% |
| Yes, staff "did" give patients information about help after discharge | 85% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 72% |
| Doctors "always" treated them with courtesy and respect | 80% |
| Patients who gave a rating of "9" or "10" (high) | 72% |
| Staff "always" explained new medications | 70% |
| Nurses "always" explained things so they could understand | 68% |
| Nurses "always" listened carefully | 68% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 48% |
| "YES", patients would definitely recommend the hospital | 76% |
| Staff "always" explained possible side effects | 43% |
| Yes, staff "did" give patients information about possible symptoms | 85% |
See every measure and the patient survey for Novato Community Hospital
Behind the star rating — Deaths: 0 better, 5 the same, 0 worse of 5 measures. Safety: 0 better, 3 the same, 0 worse of 3 measures. Readmissions: 0 better, 7 the same, 0 worse of 7 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1 (0 to 2.06) · 213 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.85 (0.4 to 1.3) | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 8.2 · 25 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10 · 111 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 16.1 · 140 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 11.3 · 42 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.8 · 627 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.2 (0 to 0.43) · 1,872 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.25 (0.04 to 0.46) · 1,796 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.92 (0.5 to 5.33) · 505 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.64 (0 to 3.36) · 317 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.2 (0.51 to 3.88) · 495 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.93 (0 to 17.29) · 323 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.88 (0.69 to 9.07) · 311 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.75 (0.22 to 3.27) · 96 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.41 (0 to 1.49) · 1,320 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.2 · 143 cases | None | Apr 2023 – Mar 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.6 · 108 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -31.9 · 121 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 1.1 · 150 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.6 · 143 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.4 · 118 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 27 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.5 (9.5 to 16.5) · 930 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.3) · 184 cases | No different | Jan 2024 – Dec 2024 |
What patients said (334 patients answered, 30% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 78% |
| Nurses "always" communicated well | 81% |
| Doctors "always" communicated well | 83% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 78% |
| Doctors "always" listened carefully | 84% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 82% |
| Staff "always" explained new medications | 77% |
| Nurses "always" explained things so they could understand | 76% |
| Nurses "always" listened carefully | 82% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 84% |
| Staff "always" explained possible side effects | 49% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Medicaid work
$371,069 in 2024
Medicaid paid $371,069 for 5,131 billed services this clinician did in 2024, up to 165 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Clinic visit/encounter, all-inclusive | 1,623 | $362,147 |
| Return visit (30+ min) | 2,070 | $4,432 |
| Short return visit (20+ min) | 1,117 | $1,330 |
| Arthrocentesis and injection of knee joint | 55 | $1,282 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 178 | $922 |
| Tetanus, diphtheria toxoids and acellular pertussis vaccine (Tdap), when administered to individuals 7 years or older, for intramuscular use | 24 | $605 |
| Influenza virus vaccine, trivalent (IIV3), split virus, 0.5 mL dosage, for intramuscular use | 21 | $240 |
| Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid) | 30 | $103 |
| Hemoglobin A1C level | 13 | $9 |
| 2024 | 5,131 | 9 | 165 | $371,069 |
| 2023 | 3,742 | 9 | 167 | $389,841 |
| 2022 | 2,417 | 5 | 149 | $272,588 |
| 2021 | 881 | 5 | 142 | $102,989 |
See the largest Medicaid services in earlier years
2023
| Clinic visit/encounter, all-inclusive | 1,814 | $388,338 |
| Return visit (30+ min) | 1,189 | $1,030 |
| Short return visit (20+ min) | 654 | $192 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, 0.5 mL dosage, for intramuscular use | 14 | $150 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 22 | $114 |
| Hemoglobin A1C level | 13 | $17 |
| Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, booster dose | 12 | $0 |
| Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid) | 12 | $0 |
| Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use | 12 | $0 |
2022
| Clinic visit/encounter, all-inclusive | 1,316 | $272,489 |
| Return visit (30+ min) | 525 | $75 |
| Short return visit (20+ min) | 514 | $24 |
| OFFICE/OUTPATIENT NEW SF MDM 15 MINUTES | 15 | $0 |
| Short return visit | 47 | $0 |
2021
| Clinic visit/encounter, all-inclusive | 497 | $102,953 |
| Short return visit | 78 | $36 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, 0.5 mL dosage, for intramuscular use | 12 | $0 |
| Short return visit (20+ min) | 162 | $0 |
| Return visit (30+ min) | 132 | $0 |
Drugs they prescribed that Part D paid
$319,665
Pharmacies billed $319,665 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 2% of their Part D prescriptions (53 of 2,260) in 2024. Above the middle of the specialty; the typical family practice clinician is at 2%.
1,948 generic and 297 brand-name prescriptions · $319,665 in drug cost · 36 antibiotic prescriptions to 22 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Biktarvy | 16 | $61,685 | $3,855 |
| Triumeq | 16 | $58,756 | $3,672 |
| Descovy | 12 | $30,112 | $2,509 |
| Eliquis | 18 | $10,426 | $579 |
| Myrbetriq | 12 | $10,159 | $847 |
See all 59 drugs
| Biktarvy | 16 | $61,685 | $3,855 |
| Triumeq | 16 | $58,756 | $3,672 |
| Descovy | 12 | $30,112 | $2,509 |
| Eliquis | 18 | $10,426 | $579 |
| Myrbetriq | 12 | $10,159 | $847 |
| Rybelsus | 12 | $9,069 | $756 |
| Combivent Respimat | 13 | $7,257 | $558 |
| Spiriva Respimat | 11 | $5,585 | $508 |
| Incruse Ellipta | 14 | $4,987 | $356 |
| Lubiprostone | 13 | $3,770 | $290 |
| Advair Hfa | 12 | $3,424 | $285 |
| Buprenorphine-Naloxone | 17 | $2,576 | $152 |
| Gabapentin | 138 | $1,668 | $12 |
| Albuterol Sulfate Hfa | 38 | $1,619 | $43 |
| Atorvastatin | 170 | $1,537 | $9 |
| Dutasteride | 14 | $1,455 | $104 |
| Celecoxib | 15 | $967 | $64 |
| Ventolin Hfa | 15 | $780 | $52 |
| Levothyroxine | 59 | $741 | $13 |
| Lactulose | 23 | $702 | $31 |
| Naproxen | 44 | $683 | $16 |
| Metformin | 83 | $641 | $8 |
| Tamsulosin | 49 | $636 | $13 |
| Diclofenac | 20 | $601 | $30 |
| Hydrocodone-Acetaminophen | 25 | $601 | $24 |
| Valacyclovir | 20 | $589 | $29 |
| Oxycodone | 16 | $550 | $34 |
| Metoprolol | 48 | $509 | $11 |
| Baclofen | 21 | $465 | $22 |
| Trazodone | 35 | $461 | $13 |
| Omeprazole | 35 | $453 | $13 |
| Fluticasone Propionate | 31 | $446 | $14 |
| Famotidine | 41 | $445 | $11 |
| Pantoprazole | 30 | $431 | $14 |
| Hydroxyzine | 12 | $377 | $31 |
| Losartan | 61 | $376 | $6 |
| Glipizide Er | 14 | $375 | $27 |
| Chlorthalidone | 22 | $341 | $15 |
| Alendronate | 32 | $336 | $10 |
| Lisinopril | 72 | $329 | $5 |
| Buprenorphine | 12 | $275 | $23 |
| Testosterone | 11 | $253 | $23 |
| Clonazepam | 36 | $228 | $6 |
| Ipratropium | 12 | $181 | $15 |
| Amlodipine Besylate | 75 | $170 | $2 |
| Montelukast | 18 | $146 | $8 |
| Escitalopram | 14 | $145 | $10 |
| Lorazepam | 31 | $143 | $5 |
| Temazepam | 11 | $135 | $12 |
| Hydrocortisone | 15 | $122 | $8 |
| Losartan-Hydrochlorothiazide | 17 | $117 | $7 |
| Allopurinol | 11 | $101 | $9 |
| Lisinopril-Hydrochlorothiazide | 14 | $91 | $6 |
| Simvastatin | 18 | $59 | $3 |
| Ibuprofen | 16 | $49 | $3 |
| Diazepam | 12 | $41 | $3 |
| Zolpidem | 11 | $39 | $4 |
| Meloxicam | 28 | $27 | $1 |
| Metoprolol | 11 | $19 | $2 |
Year by year
| 2024 | 2,260 | 166 | 2% (53) | 13% | $319,665 |
| 2023 | 1,661 | 144 | 2% (35) | 13% | $228,453 |
| 2022 | 834 | 113 | 3% (21) | None | $104,746 |
| 2021 | 297 | 59 | None | None | $78,147 |
| 2020 | 227 | 35 | 0% (0) | 7% | $22,545 |
| 2019 | 114 | 24 | 0% (0) | None | $7,055 |
| 2018 | 21 | None | 0% (0) | None | $383 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 43 drugs
| Trulicity | 12 | $13,975 | $1,165 |
| Januvia | 11 | $12,289 | $1,117 |
| Myrbetriq | 19 | $9,710 | $511 |
| Suboxone | 13 | $7,570 | $582 |
| Advair Diskus | 14 | $7,016 | $501 |
| Combivent Respimat | 13 | $6,674 | $513 |
| Oxycodone | 12 | $4,124 | $344 |
| Atorvastatin | 146 | $4,067 | $28 |
| Buprenorphine-Naloxone | 11 | $2,201 | $200 |
| Amlodipine Besylate | 91 | $2,066 | $23 |
| Gabapentin | 66 | $1,977 | $30 |
| Tamsulosin | 39 | $1,702 | $44 |
| Lisinopril | 64 | $1,612 | $25 |
| Metformin | 71 | $1,285 | $18 |
| Ventolin Hfa | 20 | $1,237 | $62 |
| Fluticasone Propionate | 36 | $1,075 | $30 |
| Losartan | 38 | $1,044 | $27 |
| Diclofenac | 20 | $898 | $45 |
| Terazosin | 11 | $792 | $72 |
| Celecoxib | 25 | $750 | $30 |
| Clonazepam | 28 | $696 | $25 |
| Omeprazole | 24 | $639 | $27 |
| Famotidine | 27 | $560 | $21 |
| Tizanidine | 23 | $538 | $23 |
| Pantoprazole | 25 | $536 | $21 |
| Levothyroxine | 31 | $533 | $17 |
| Baclofen | 11 | $516 | $47 |
| Chlorthalidone | 12 | $472 | $39 |
| Metoprolol | 28 | $450 | $16 |
| Simvastatin | 18 | $403 | $22 |
| Trazodone | 23 | $385 | $17 |
| Lisinopril-Hydrochlorothiazide | 12 | $350 | $29 |
| Buprenorphine | 13 | $327 | $25 |
| Lorazepam | 18 | $278 | $15 |
| Zolpidem | 19 | $268 | $14 |
| Ketoconazole | 12 | $251 | $21 |
| Montelukast | 12 | $233 | $19 |
| Citalopram Hbr | 13 | $187 | $14 |
| Furosemide | 14 | $162 | $12 |
| Naproxen | 16 | $152 | $10 |
| Ibuprofen | 13 | $142 | $11 |
| Triamcinolone Acetonide | 14 | $102 | $7 |
| Diazepam | 13 | $46 | $4 |
2022: 20 drugs
| Triumeq | 11 | $39,668 | $3,606 |
| Lantus Solostar | 15 | $4,531 | $302 |
| Atorvastatin | 65 | $1,236 | $19 |
| Gabapentin | 26 | $835 | $32 |
| Amlodipine Besylate | 59 | $579 | $10 |
| Lisinopril | 34 | $475 | $14 |
| Tamsulosin | 16 | $473 | $30 |
| Metformin | 33 | $463 | $14 |
| Fluticasone Propionate | 18 | $373 | $21 |
| Buprenorphine | 11 | $277 | $25 |
| Carvedilol | 14 | $224 | $16 |
| Simvastatin | 11 | $204 | $19 |
| Omeprazole | 14 | $185 | $13 |
| Furosemide | 11 | $163 | $15 |
| Clonazepam | 14 | $157 | $11 |
| Losartan | 18 | $156 | $9 |
| Diazepam | 15 | $123 | $8 |
| Ibuprofen | 16 | $101 | $6 |
| Tizanidine | 12 | $92 | $8 |
| Trazodone | 13 | $71 | $5 |
2021: 6 drugs
| Biktarvy | 16 | $59,503 | $3,719 |
| Atorvastatin | 25 | $372 | $15 |
| Gabapentin | 14 | $363 | $26 |
| Amlodipine Besylate | 19 | $92 | $5 |
| Sertraline | 13 | $84 | $6 |
| Hydrochlorothiazide | 12 | $30 | $2 |
2020: 6 drugs
| Mesalamine | 11 | $4,685 | $426 |
| Trazodone | 22 | $184 | $8 |
| Gabapentin | 13 | $135 | $10 |
| Lisinopril | 15 | $108 | $7 |
| Metoprolol | 11 | $70 | $6 |
| Amlodipine Besylate | 14 | $60 | $4 |
2019: 3 drugs
| Trazodone | 12 | $140 | $12 |
| Sertraline | 12 | $91 | $8 |
| Hydrochlorothiazide | 11 | $44 | $4 |
Money from drug and device companies
$34 in 2025
| 2025 | 1 | 1 | None | $34 |
| 2024 | 2 | 3 | None | $69 |
| 2022 | 1 | 1 | None | $81 |
| 2019 | 1 | 1 | None | $81 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Gilead Sciences | None | $34 | 1 payment
|
See the published payment
| Gilead Sciences | Meals · 2025-12-17 | None | $34 |
See earlier years (2024, 2022, 2019)
2024: $69
| Scilex Pharmaceuticals | Ztlido | $43 | 2 payments
|
| ViiV Healthcare | Cabenuva | $27 | 1 payment
|
2022: $81
| Abbott Laboratories | Proclaim | $81 | 1 payment
|
2019: $81
| AbbVie | Mavyret | $81 | 1 payment
|
Professional record
- NPI
- 1013414507
- Licence
- CA 20A19053
- Trained
- University of Texas at Austin Dell Medical School, 2018 · 8 years ago
- Group
- Carbon Health Medical Group of California PC · Marin Community Clinic · One Medical Group Inc
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Family medicine (207Q00000X)
- Mailing address
- 5 Bon Air Rd Ste 117, Larkspur, CA, 94939
- NPI first listed
- 2018-04-10
- NPI last updated
- 2025-09-19
- NPI record certified
- 2025-09-19
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 2355 Market St, San Francisco, CA, 94114